JP6611710B2 - 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 - Google Patents

脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Download PDF

Info

Publication number
JP6611710B2
JP6611710B2 JP2016527092A JP2016527092A JP6611710B2 JP 6611710 B2 JP6611710 B2 JP 6611710B2 JP 2016527092 A JP2016527092 A JP 2016527092A JP 2016527092 A JP2016527092 A JP 2016527092A JP 6611710 B2 JP6611710 B2 JP 6611710B2
Authority
JP
Japan
Prior art keywords
biomarker
tbi
bdnf
level
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533499A (ja
JP2016533499A5 (enExample
Inventor
アレン ディー エヴェレット
エイク ジェニファー イー ヴァン
フレッド コーリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2016533499A publication Critical patent/JP2016533499A/ja
Publication of JP2016533499A5 publication Critical patent/JP2016533499A5/ja
Priority to JP2019195925A priority Critical patent/JP6980291B2/ja
Application granted granted Critical
Publication of JP6611710B2 publication Critical patent/JP6611710B2/ja
Priority to JP2021181686A priority patent/JP2022023999A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/825—Metallothioneins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
JP2016527092A 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Active JP6611710B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019195925A JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847213P 2013-07-17 2013-07-17
US61/847,213 2013-07-17
PCT/US2014/046986 WO2015009907A1 (en) 2013-07-17 2014-07-17 A multi-protein biomarker assay for brain injury detection and outcome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019195925A Division JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット

Publications (3)

Publication Number Publication Date
JP2016533499A JP2016533499A (ja) 2016-10-27
JP2016533499A5 JP2016533499A5 (enExample) 2017-08-24
JP6611710B2 true JP6611710B2 (ja) 2019-11-27

Family

ID=52346714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016527092A Active JP6611710B2 (ja) 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Country Status (5)

Country Link
US (4) US10534003B2 (enExample)
EP (2) EP3757226A3 (enExample)
JP (3) JP6611710B2 (enExample)
IL (1) IL243393A0 (enExample)
WO (1) WO2015009907A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12172017B2 (en) * 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2015009907A1 (en) 2013-07-17 2015-01-22 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016125148A1 (en) 2015-02-05 2016-08-11 Immunarray Ltd. Methods and compositions for diagnosing brain injury or neurodegeneration
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
FI20155280A7 (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
US10244971B2 (en) * 2015-05-12 2019-04-02 International Business Machines Corporation Mouthguard for analysis of biomarkers for traumatic brain injury
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP4521116A3 (en) * 2016-10-03 2025-05-28 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) * 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
CA3261113A1 (en) 2017-03-23 2025-10-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CN110546513A (zh) 2017-04-15 2019-12-06 雅培实验室 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
ES3053676T3 (en) 2017-04-28 2026-01-23 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US11709168B2 (en) 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
AU2018272054B2 (en) 2017-05-25 2024-10-31 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
CA3068041C (en) 2017-07-03 2024-06-25 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
EP3654032B1 (en) * 2017-07-14 2023-09-27 Mcbi Inc. Disease detection method
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
EP3721234A1 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
AU2018395255B2 (en) * 2017-12-29 2025-02-20 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2020006445A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers and treatment methods for traumatic brain injury associated impairments
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CA3128367A1 (en) * 2019-02-01 2020-08-06 Venn Biosciences Corporation Biomarkers for diagnosing ovarian cancer
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12613250B2 (en) 2019-04-30 2026-04-28 University Of Florida Research Foundation, Incorporated Biomarker panel for sepsis encephalopathy
KR102464243B1 (ko) * 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
EP3982123A1 (en) * 2020-10-08 2022-04-13 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Markers and their use in brain injury
KR102189144B1 (ko) * 2020-10-15 2020-12-09 서울대학교병원 만성신장질환 악화 예측 마커 및 이를 이용한 악화 예측 방법
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
EP4466064A4 (en) 2022-01-20 2026-01-14 Setpoint Medical Corp TREATMENT OF INFLAMMATORY DISORDERS
FI130340B (en) * 2022-02-22 2023-06-29 Medicortex Finland Oy Procedure for the diagnosis of traumatic brain injury
CN114594273B (zh) * 2022-05-09 2024-02-27 上海众启生物科技有限公司 一种脑梗塞生物标记物及其应用
WO2023239621A1 (en) * 2022-06-05 2023-12-14 Branelie Health, Inc. Healthcare system for and methods of managing brain injury or concussion
JP7489723B2 (ja) * 2022-10-05 2024-05-24 和哉 松尾 プログラム、情報処理装置、情報処理方法、および学習モデルの生成方法
WO2025188805A1 (en) * 2024-03-04 2025-09-12 University Of Denver Blood based rapid diagnostic system for brain hemorrhage detection and associated methods

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
WO1994028418A1 (en) 1993-05-28 1994-12-08 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
KR100449615B1 (ko) 1995-03-10 2004-12-08 메소 스케일 테크놀러지즈, 엘엘시 다-배열,다-특이적전기화학발광시험법
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
EP0874993A1 (en) 1995-12-22 1998-11-04 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
WO2001031580A2 (en) 1999-10-27 2001-05-03 Biowulf Technologies, Llc Methods and devices for identifying patterns in biological systems
AU2001280581A1 (en) 2000-07-18 2002-01-30 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
US20020164576A1 (en) 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
WO2002024867A2 (en) 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
WO2002042733A2 (en) 2000-11-16 2002-05-30 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
WO2003016910A1 (en) 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
EP2420824B1 (en) 2001-06-29 2018-11-28 Meso Scale Technologies LLC Multi-well plate having an array of wells and kit for use in the conduct of an ECL assay
US8815577B2 (en) 2001-07-30 2014-08-26 Meso Scale Technologies, Llc Assay electrode having immobilized lipid/protein layers, methods of making the same and methods of using the same for luminescence test measurements
CA2932756C (en) 2001-09-10 2020-07-07 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
US7063946B2 (en) 2001-09-10 2006-06-20 Meso Scale Technologies, Llc. Methods, reagents, kits and apparatus for protein function analysis
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
DK1456668T3 (da) 2001-12-05 2007-09-10 Sense Proteomic Ltd Proteinarrays til alleliske varianter og anvendelser deraf
CA2473108A1 (en) 2002-01-14 2003-07-24 Henry Ford Health System Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
EP1587955A4 (en) * 2002-12-24 2007-03-14 Biosite Inc DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE
CA3122193C (en) 2002-12-26 2025-05-06 Meso Scale Technologies, Llc. ANALYSIS CARTRIDGES AND THEIR METHODS OF USE
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
AU2005238446B2 (en) 2004-04-15 2009-07-30 Banyan Biomarkers Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
EP1774023B1 (en) 2004-06-25 2013-05-01 Washington University School Of Medicine Markers for brain damage
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
JP5240945B2 (ja) 2006-11-28 2013-07-17 ピクター リミテッド アッセイ膜およびその使用法
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
EP2245466A2 (en) 2008-02-04 2010-11-03 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
US8497078B2 (en) 2008-05-23 2013-07-30 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100190656A1 (en) 2008-08-08 2010-07-29 Integrated Diagnostics, Inc. Breast Cancer Specific Markers and Methods of Use
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
AU2009282117B2 (en) 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP3355059A3 (en) * 2009-06-19 2018-09-26 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
HUE040281T2 (hu) 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantitest markerek traumás agysérülés diagnózisára
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2628013B1 (en) * 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
CN105823887B (zh) 2011-01-28 2018-06-12 西瑞斯实验室有限公司 用于检测肠和血脑屏障通透性的方法及其测试材料
JP2014518624A (ja) * 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
US20150119273A1 (en) 2012-05-16 2015-04-30 Trustees Of Boston University Chronic Traumatic Encephalopathy in Blast-Exposed Individuals
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
WO2015009907A1 (en) 2013-07-17 2015-01-22 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition

Also Published As

Publication number Publication date
EP3022322A4 (en) 2017-05-17
US20230077876A1 (en) 2023-03-16
EP3757226A2 (en) 2020-12-30
JP6980291B2 (ja) 2021-12-15
EP3757226A3 (en) 2021-05-05
WO2015009907A1 (en) 2015-01-22
JP2022023999A (ja) 2022-02-08
JP2016533499A (ja) 2016-10-27
US12339288B2 (en) 2025-06-24
EP3022322A1 (en) 2016-05-25
US10534003B2 (en) 2020-01-14
JP2020034567A (ja) 2020-03-05
US20160178643A1 (en) 2016-06-23
US11499982B2 (en) 2022-11-15
US20260043814A1 (en) 2026-02-12
US20200116739A1 (en) 2020-04-16
IL243393A0 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP6980291B2 (ja) 脳損傷の診断／予後判定／評価において有用な組成物及びキット
US20260063646A1 (en) Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
US12461112B2 (en) Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US20250044303A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
US20230238143A1 (en) Multimodality systems and methods for detection, prognosis, and monitoring of neurological injury and disease
JP6071886B2 (ja) 脳損傷のバイオマーカー
US9678086B2 (en) Diagnostic assay for Alzheimer's disease
EP3245520B1 (en) Serum biomarker panels for bipolar disorder
US20140147874A1 (en) Biomarkers of cardiac ischemia
US20250035650A1 (en) Biomarker testing for chronic persistent injury following brain trauma
US20250155455A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
WO2025179300A1 (en) Biomarkers, compositions, kits, and methods distinguishing acute geriatric tbi from pre-existing dementia or cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160229

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250